Oleg Movchan Sells 2,771 Shares of Enfusion, Inc. (NYSE:ENFN) Stock

Enfusion, Inc. (NYSE:ENFN) CEO Oleg Movchan sold 2,771 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total transaction of $28,070.23. Following the sale, the chief executive officer now directly owns 526,702 shares of the company’s stock, valued at $5,335,491.26. This trade represents a 0.52 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Enfusion Price Performance

Enfusion stock traded down $0.32 during mid-day trading on Friday, reaching $9.97. 351,403 shares of the stock traded hands, compared to its average volume of 388,016. Enfusion, Inc. has a 12-month low of $7.52 and a 12-month high of $11.38. The business’s 50-day moving average is $10.09 and its 200-day moving average is $9.18. The stock has a market capitalization of $1.28 billion, a PE ratio of 249.31, a price-to-earnings-growth ratio of 3.98 and a beta of 0.95.

Institutional Investors Weigh In On Enfusion

Hedge funds and other institutional investors have recently made changes to their positions in the business. Arizona State Retirement System bought a new position in shares of Enfusion in the second quarter worth about $86,000. Harbor Capital Advisors Inc. raised its stake in Enfusion by 12.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after acquiring an additional 1,315 shares during the period. Belvedere Trading LLC purchased a new position in Enfusion during the third quarter valued at approximately $114,000. Paloma Partners Management Co bought a new position in shares of Enfusion in the third quarter worth approximately $157,000. Finally, The Manufacturers Life Insurance Company raised its position in shares of Enfusion by 27.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock valued at $167,000 after purchasing an additional 4,239 shares during the period. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Analyst Ratings Changes

ENFN has been the topic of several recent analyst reports. Stifel Nicolaus increased their target price on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Piper Sandler increased their price objective on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research report on Monday, December 23rd. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.25.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.